Trial Profile
Open-label study ACT-385781A in patients with pulmonary arterial hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jun 2016
Price :
$35
*
At a glance
- Drugs Epoprostenol (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Registrational
- Sponsors Actelion Pharmaceuticals
- 07 Jun 2016 New trial record